Mehrdad Mobasher
About Mehrdad Mobasher
Mehrdad Mobasher is the Chief Medical Officer, Hematology at BeiGene in San Mateo, California. He has extensive experience in clinical development and leadership roles in the pharmaceutical and biotech industries.
Chief Medical Officer, Hematology at BeiGene
Mehrdad Mobasher currently serves as Chief Medical Officer, Hematology at BeiGene in San Mateo, California. Since joining BeiGene in August 2022, Mobasher has been instrumental in overseeing the clinical development of various hematology-focused therapies. His role includes managing clinical trials and guiding therapeutic research to advance hematology treatment options.
Previous Roles in Oncology and Hematology Management
Before joining BeiGene, Mehrdad Mobasher was the Senior Vice President and Global Head of Late-Stage Oncology Development at Zai Lab, where he worked from 2021 to 2022. He has also served as Chief Medical Officer at Corvus Pharmaceuticals from 2019 to 2021, where he led the development pipeline for solid tumors, COVID-19 treatments, and T-cell lymphomas. Additionally, Mobasher held various leadership roles at Genentech, including Group Medical Director - Hematology, Cross-Indication Development Lead, and Assoc. Group Medical Director.
Educational Background and Fellowships
Mehrdad Mobasher has a robust academic background in medical sciences. He completed his M.D. at the University of Tehran in 1998. He also holds an M.P.H. in Epidemiology from the University of Michigan. Mobasher completed his residency in Internal Medicine at UC Irvine from 2004 to 2007 and later pursued fellowships in Hematology and Medical Oncology at Stanford University from 2007 to 2010. He has also been an adjunct clinical faculty member in the Division of Medical Oncology at Stanford University.
Experience in Clinical Development and Trials
With extensive experience in managing clinical trials across all phases, from pre-clinical to phase 1-3 studies, Mehrdad Mobasher has been pivotal in the clinical development of multiple therapeutic agents. These include monoclonal antibodies, small molecules, targeted agents, and immunotherapies. His work spans a variety of therapeutic indications, including hematology, immuno-oncology, solid tumors, and COVID-19.
Leadership in Pharmaceutical and Biotech Industries
Throughout his career, Mehrdad Mobasher has demonstrated a strong track record of building and leading cross-functional teams. His leadership roles at Zai Lab, Corvus Pharmaceuticals, and Genentech underscored his ability to manage and execute large-scale clinical development projects. His extensive experience in the pharmaceutical and biotech industries has equipped him with the skills to guide and mentor teams towards achieving clinical and operational excellence.